Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Public ClinicalTrials.gov record NCT07232030. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure (BENEFIT-HF)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF \< 50% and NT-proBNP \< 5,000 pg/mL despite being treated with Guideline-Directed Medical Therapies (medications and devices). It includes demonstration that treatment with the Barostim System, relative to usual care medical management, reduces the rate of all-cause mortality and Heart Failure Morbidity (Cardiac Transplant, Durable LVAD, or Worsening Heart Failure Events).
Study identification
- NCT ID
- NCT07232030
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 2,500 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2026
- Primary completion
- Dec 31, 2032
- Completion
- Dec 31, 2032
- Last update posted
- Sep 1, 2026
2026 – 2033
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cardiology Associates of Mobile | Mobile | Alabama | 36608 | Recruiting |
| BayCare Health System | Clearwater | Florida | 33756 | Recruiting |
| First Coast Cardiovascular Institute | Jacksonville | Florida | 32256 | Recruiting |
| Tallahassee Research Institute | Tallahassee | Florida | 32308 | Recruiting |
| BayCare Health Systems | Tampa | Florida | 33614 | Recruiting |
| The Christ Hospital | Cincinnati | Ohio | 45219 | Recruiting |
| North Central Heart | Sioux Falls | South Dakota | 57108 | Recruiting |
| Erlanger Health | Chattanooga | Tennessee | 37403 | Recruiting |
| CHRISTUS Trinity Mother Frances | Tyler | Texas | 75701 | Recruiting |
| Marshfield Clinic Research Institute | Marshfield | Wisconsin | 54449 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07232030, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07232030 live on ClinicalTrials.gov.